
    
      Patients who participated in the placebo controlled phase of this study and opted to continue
      receiving open label GW-1000-02 entered the follow-on extension of the study and completed
      symptom assessments to determine whether they were continuing to receive clinical benefit
      from GW-1000-02.
    
  